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Background: The purpose of this study was to investigate the 12-month outcome of macular 
edema secondary to both chronic and new central and branch retinal vein occlusions treated 
with intravitreal bevacizumab in the real-life clinical setting in the UK.
Methods: Retrospective case notes analysis of consecutive patients with retinal vein occlusions 
treated with bevacizumab in 2010 to 2012. Outcome measures were visual acuity (measured 
with Snellen, converted into logMAR [logarithm of the minimum angle of resolution] for 
statistical calculation) and central retinal thickness at baseline, 4 weeks post-loading phase, 
and at 1 year.
Results: There were 56 and 100 patients with central and branch retinal vein occlusions, 
respectively, of whom 62% had chronic edema and received prior therapies and another 32% 
required additional laser treatments post-baseline bevacizumab. Baseline median visual acuity 
was 0.78 (interquartile range [IQR] 0.48–1.22) in the central group and 0.6 (IQR 0.3–0.78) in 
the branch group. In both groups, visual improvement was statistically significant from baseline 
compared to post-loading (P,0.001 and P=0.03, respectively), but was not significant by month 
12 (P=0.058 and P=0.166, respectively); 30% improved by at least three lines and 44% improved 
by at least one line by month 12. Baseline median central retinal thickness was 449 μm (IQR 
388–553) in the central group and 441 μm (IQR 357–501) in the branch group. However, the 
mean reduction in thickness was statistically significant at post-loading (P,0.001) and at the 
12-month time point (P,0.001) for both groups. The average number of injections in 1 year 
was 4.2 in the central group and 3.3 in the branch group.
Conclusion: Our large real-world cohort results indicate that bevacizumab introduced to 
patients with either new or chronic edema due to retinal vein occlusion can result in resolution 
of edema and stabilization of vision in the first year.
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Introduction
Retinal vein occlusion is a common cause of visual morbidity in both the elderly and 
younger populations and can be associated with cardiovascular and other systemic 
disorders.1–4
In recent years, there have been a number of well-designed, randomized clinical 
trials, demonstrating the efficacy and safety of several therapeutic agents in achieving 
visual improvement and resolution of macular edema in eyes with central retinal vein 
occlusion (CRVO) or branch retinal vein occlusion (BRVO).5–11 However, prior to the 
approval of licensed therapy by the National Institute for Health and Care Excellence 
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(NICE) for retinal vein occlusion, many ophthalmologists in 
our National Health Service used intravitreal bevacizumab 
for treatment of macular edema secondary to CRVO or 
BRVO.12–14 The pathway-orientated approach in our health 
service provides a good environment for reporting of real-
world outcomes, because the criteria used for case selection 
for initial treatment and decision-making on retreatment is 
usually very uniform and comprehensive, and free from bias 
caused by patient factors such as affordability and health 
insurance coverage. Real-world outcomes are not only helpful 
for justifying continuation of current clinical practice accord-
ing to the guidelines derived from clinical trials, but can also 
provide benchmarks for future clinical audits and possible 
signals for hypothesis generation in future clinical research.
Numerous real-world outcomes of bevacizumab have 
been published in the international literature, but to our 
knowledge, no such large study in the UK National Health 
Service setting has been published.15–18 In this study, we 
report the findings of the largest comprehensive retrospective 
audit of all consecutive patients who underwent treatment for 
macular edema secondary to CRVO or BRVO in a large ter-
tiary center using bevacizumab monotherapy as the first-line 
agent for retinal vein occlusion therapy or as an additional 
therapy for chronic macular edema refractory to previous 
laser therapy or intravitreal triamcinolone therapy.
Materials and methods
Consecutive patients commenced on treatment with intra-
vitreal bevacizumab for CRVO or BRVO in one eye at 
a teaching and tertiary referral center from 2010 to 2012 
(bevacizumab was first introduced to our department in 2010) 
were identified from our departmental database. Retrospec-
tive data collection from case notes was performed to allow 
for at least 12 months of follow-up data. This retrospective 
data review was part of our departmental audit process and 
hence no ethics approval was needed.
Chronicity of macular edema was defined as persisting 
disease (macular edema) of more than 12 months’ duration 
and previously receiving laser therapy or intravitreal steroid 
injections. All patients entering the bevacizumab retinal vein 
occlusion program followed a uniform pragmatic diagnostic 
pathway consisting of visual acuity recording using the Snellen 
chart, slit lamp ophthalmic examination, and optical coherence 
tomography (OCT) scans on every assessment visit. Central 
retinal thickness (CRT) was captured and measured (from 
retinal pigment epithelial layer to retinal surface) using Topcon 
OCT 2000. The treatment protocol consisted of an intravitreal 
loading dose of bevacizumab (one to three injections monthly, 
at the discretion of the treating consultant), followed by repeat 
injections as clinically indicated if there was persistent or 
worsening of CRT on follow-up OCT scans. All patients were 
reviewed 4 weeks post last injection of loading dose, then 4–8 
weekly if stable. Data collected from the case notes of each 
patient included demographics, presence of preexisting glau-
coma (including ocular hypertension), bilateral or unilateral 
treatment, number of injections, visual acuity of treated eyes 
at baseline, post-loading, and at month 12, and history of prior 
laser or intravitreal corticosteroid therapy. OCT scans for all 
patients were reviewed to collect data on CRT and the pres-
ence of subretinal fluid at baseline and at the 1-year time point. 
Snellen fractions were converted to noncontinuous logMAR 
(logarithm of the minimum angle of resolution) units by a 
standard conversion method for statistical purposes.19,20
Descriptive statistics were used to show demographics, 
baseline characteristics, and preexisting risk factors such 
as glaucoma and cardiovascular status. “Glaucoma” in our 
series was defined as high intraocular pressure more than 
21 mmHg with or without visual field defect, but using at 
least one topical anti-glaucoma treatment. Data analysis 
was separately performed for CRVO and BRVO patients to 
investigate change in visual and anatomical outcomes after 
initial loading phase and at the 1-year time point. Changes 
of visual acuity and CRT measurements at these time points 
from baseline were tested for statistical significance using 
the Wilcoxon signed-rank test.
Results
Demographics and baseline characteristics
Of 156 patients, 56 had CRVO and 100 had BRVO. All 
patients had unilateral bevacizumab. All patients completed 
12 months of follow-up, but five patients with CRVO were 
followed up in peripheral units prior to their month 12 visits. 
In these five patients, final visual acuity at month 12 was 
obtainable, but their 12-month CRT measurements were not 
obtainable. For CRVO and BRVO, respectively, the mean 
age was 69 years and 71 years, and males comprised 46% 
and 51% (Table 1). Baseline median visual acuity in logMAR 
Table 1 Demographic and baseline characteristics
CRVO (n=56) BRVO (n=100)
Mean age, years (sD; range) 69 (12.2; 34–87) 71 (11.05; 43–94)
sex, male/female 26/30 51/49
Mean number of injections  
in 1 year (mode, range)
4.2 (3; 1–9) 3.3 (3; 1–9)
loading frequency 1:2:3 13:9:34 20:21:59
Abbreviations: CrVO, central retinal vein occlusion; BrVO, branch retinal vein 
occlusion; sD, standard deviation.
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Table 2 Baseline and changes in vision and central retinal thickness with bevacizumab therapy
CRVO group BRVO group
Visual changes in logMAR (Snellen equivalent), compared with baseline
Baseline median Va [iQr] 0.78 (6/36) [0.48–1.22] 0.60 (6/24) [0.30–0.78]
Median Va post-loading [iQr] 0.69 (6/30) [0.18–1.0], P=0.03 0.48 (6/18) [0.30–0.70], P,0.001
Median Va at 12 months [iQr] 0.78 (6/36) [0.30–1.30], P=0.166 0.54 (6/20) [0.30–0.78], P=0.058
Three-line visual improvement at 12 months 30% 24%
One-line visual improvement at 12 months 44% 51%
CRT changes (μm) versus baseline
Baseline median CrT [iQr] 449 [388–553] 411 [357–501]
Median CrT [iQr] post-loading 287 [237–402], P,0.001 309 [260–437], P,0.001
Median CrT [iQr] at 12 months 278 [229–495], P,0.001 335 [261–447], P,0.001
Abbreviations: CrVO, central retinal vein occlusion; BrVO, branch retinal vein occlusion; Va, visual acuity; iQr, interquartile range (statistical analysis using Wilcoxon 
signed-rank test); CrT, central retinal thickness; logMar, logarithm of the minimum angle of resolution.
Table 3 Preexisting risk factors, previous therapy, and adverse effects
CRVO (n=56) BRVO (n=100)
Recorded risk factors
Known cardiovascular risks 26 (46%) 36 (36%)
referral to cardiovascular assessment (recorded in notes) 10 (18%) 10 (10%)
Known glaucoma/ocular hypertension 20 (36%) 14 (14%)
Chronicity indication
had previous laser therapy 25 (45%) 36 (36%)
had previous triamcinolone 11 (20%) 2 (2%)
Adverse effects
raised iOP 2 (4%)
1 (rubeotic glaucoma)
5 (5%)
Corneal abrasion 0 2 (2%)
endophthalmitis 0 0
Abbreviations: CrVO, central retinal vein occlusion; BrVO, branch retinal vein occlusion; iOP, intraocular pressure.
units was 0.78 (Snellen 6/36) and 0.60 (Snellen 6/24) and 
baseline median CRT was 449 μm and 441 μm in CRVO and 
BRVO, respectively (Table 2). The mean number of injec-
tions over 12 months was 4.2 and 3.3, respectively, for CRVO 
and BRVO (Table 1). Prior treatment included laser therapy 
(namely macular laser and/or pan-retinal photocoagulation as 
clinically indicated by ischemia) in 45% of CRVO eyes and 
36% of BRVO eyes, and intravitreal triamcinolone in 20% 
of CRVO eyes and 2% of BRVO eyes. On baseline OCT, 
the presence of subretinal fluid was found in 57% of CRVO 
eyes and 81% of BRVO eyes.
In terms of preexisting risk factors, we found that a high 
percentage of patients had glaucoma: 36% in CRVO group, 
14% in BRVO group; and cardiovascular disease was known 
in 46% of CRVO and 36% of BRVO patients (Table 3).
Visual outcome
At the post-loading review, in CRVO eyes, median visual 
acuity was logMAR 0.69 (interquartile range [IQR] 0.18–1.0), 
but was reduced to 0.78 (IQR 0.3–1.3) at the month 12 
visit (Table 2). The improvement from baseline to the 
post-loading visit was statistically significant (P=0.03), but 
the improvement from baseline to month 12 was not signifi-
cant (P=0.166). In terms of proportion of patients improving, 
30% improved by at least three lines and 44% improved by 
at least one line by month 12.
Similarly, in BRVO eyes at post-loading review, median 
visual acuity was 6/18 or logMAR 0.48 (IQR 0.3–0.7), but was 
6/20 or logMAR 0.54 (IQR 0.3–0.78) at the month 12 visit. 
The improvement from baseline to the post-loading visit was 
significant (P,0.001), but the improvement from baseline to 
month 12 was not significant (P=0.058). In terms of propor-
tions of patients improving, 24% improved by at least three 
lines and 51% improved by at least one line by month 12.
anatomical outcomes
Based on a total of 51 CRVO eyes with a complete CRT 
dataset, median CRT improved to 287 μm (IQR 237–402) 
post-loading, and to 278 μm (IQR 229–495) at month 12 
(Table 2). Median reduction in CRT from baseline was 
statistically significant at the post-loading visit (P,0.001) 
as well as at the month 12 visit (P,0.001).
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In the BRVO eyes, median CRT improved to 309 μm 
(IQR 260–437) post-loading and to 335 μm (IQR 261–447) 
at month 12. The median change in CRT from baseline was 
statistically significant at the post-loading visit (P,0.001) 
and at month 12 (P,0.001).
Thirty-two of 56 (57%) CRVO eyes that had subretinal 
fluid at baseline achieved a mean logMAR visual acuity of 0.84 
(Snellen equivalent of 6/40) at month 12. This was numerically 
slightly worse compared to that achieved by the whole cohort 
of CRVO eyes. Eighty-one of 100 (81%) BRVO eyes that 
had subretinal fluid at baseline achieved a median logMAR 
visual acuity of 0.55 (Snellen equivalent of 6/20) at month 12. 
This was numerically similar to that achieved by the whole 
cohort of BRVO eyes.
adverse events
One patient developed mild ocular hypertension and another 
progressed to rubeotic glaucoma in the CRVO group. In 
the BRVO group, five patients had mild controlled ocular 
hypertension and two patients had corneal abrasion. There 
was no endophthalmitis in our series (Table 3).
Discussion
Since 2008, prospective studies of bevacizumab have pro-
vided the necessary evidence base for ophthalmologists 
worldwide to use such an unlicensed therapy for retinal vein 
occlusion.15,18 In many centers, including ours, prior to NICE 
approval of ranibizumab for retina vein occlusion in 2013,13 
bevacizumab was used as the anti-vascular endothelial 
growth factor (VEGF) agent of choice for patients with retinal 
vein occlusion. Although there are fewer real-world studies of 
retinal vein occlusion using bevacizumab than ranibizumab, 
it is still a challenge to make a limited comparison of small 
numbers. For example, more recently, the MARVEL group 
published a prospective, head-to-head study comparing 
bevacizumab with ranibizumab for BRVO.21 Although the 
numbers are small, the initial 6-month result suggested a 
compatible benefit of either agent in treating BRVO with 
macular edema using the “as required regime”, with an aver-
age of three to four injections needed in the first 6 months. 
In a study from Copenhagen, the authors reported real-world 
outcomes for 106 patients with retinal vein occlusion treated 
with ranibizumab, whereas in another study from Rome, 
50 eyes with CRVO were included.22,23
Thirty percentage of CRVO eyes improved by at least 
three lines and 44% improved by at least one line by month 
12. This was very similar to the proportion found in the 
Copenhagen study, although slightly less than that found in 
the CRUISE study, which reported up to 47% with a three-
line gain at month 6 and 50.8% by month 12. In BRVO 
eyes, we found that 24% improved by at least three lines and 
51% improved by at least one line by month 12.5,6 This was 
almost identical to the findings from the Copenhagen study, 
but again very much less than that reported in the BRAVO 
study (up to 60.3% with a three-line gain by month 12).22 
Reasons for the lower visual outcome may be attributable to 
the fewer injections in our population (mean 4.2 CRVO and 
3.3 BRVO in 12 months) compared with 9.3 injections in 
12 months reported in the extended CRUISE and BRAVO 
trial.7 Other reasons may be the lack of refraction on every 
visit and our reliance on OCT retreatment criteria rather 
than a low retreatment threshold using both functional and 
anatomical criteria as used in the CRUISE and BRAVO 
studies.5,6 The change could also be due to a true difference 
between ranibizumab and bevacizumab, although this seems 
unlikely, given the findings in head-to-head studies on other 
indications, such as age-related macular degeneration and 
diabetic macular edema.24–30
Our series had a variable number of injections in the load-
ing phase depending on clinician discretion, and therefore had 
an overall lower number of injections over a 12-month period. 
Despite the much lower injection rates in both CRVO and 
BRVO eyes, we found that CRT measurements were signifi-
cantly reduced and maintained at month 12. In this respect, 
our findings compare favorably with the CRUISE, BRAVO 
extension study (HORIZON), which followed patients for up 
to 2.5 years in total from their first injections.7 This suggests 
that an objective parameter such as CRT may be a suitable 
and indeed practical method to be adopted in real-world prac-
tices in the UK. The achievement of a good outcome in CRT 
with much fewer injections suggests that use of anatomical 
retreatment criteria may not only be more pragmatic, but 
may also result in reducing possible unnecessary retreatment. 
As a result of this study, since the approval of ranibizumab 
for retinal vein occlusion at our center, we have continued to 
use OCT-driven criteria where we repeat ranibizumab dosing 
if there is persistent or worsening macular edema on an as-
needed basis after a variable loading of one to three doses, 
depending on the severity of edema at baseline.
Adverse events were infrequent, highlighting the well-
established safety profile of bevacizumab in this popula-
tion. Notably, only one patient had rubeotic glaucoma after 
commencing on bevacizumab therapy. This is a recognized 
complication of ischemic retinal vein occlusion, but has not 
been reported specifically in eyes undergoing treatment with 
intravitreal bevacizumab or ranibizumab.31 This highlights 
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the need to treat peripheral retinal non-perfusion, especially 
in cases of CRVO when discontinuing injections after suc-
cessful resolution of macular edema.
It is well recognized that up to 60% of patients with retinal 
vein occlusions have systemic hypertension or cardiovas-
cular disease.4 In our retrospective series, which relied on 
extracting data from clinical notes, we found considerably 
fewer patients with associated cardiovascular conditions. We 
believe this may have been due to poor documentation by 
clinicians and also a tendency by ophthalmologists to ignore 
systemic factors when treating macular edema. Given the 
5%–10% risk of retinal vein occlusion developing in the sec-
ond eye within a 2–3-year period, it is important for us to con-
tinually highlight the importance of cardiovascular screening 
and management in this population of patients.1–4
In common with real-world studies, the major weakness 
of this study was the lack of protocol refraction and visual 
acuity measurements using research standard logMAR visual 
acuity charts. Visual acuity comparisons were therefore made 
using the Wilcoxon signed-rank test, which was appropriate 
for nonparametric data. Although we used a standard method 
of converting Snellen visual acuity to logMAR units, there 
is a known tendency to overestimate visual acuity using the 
Snellen chart at lower levels of acuity, and this may have 
occurred in our study. However, the strengths of this study 
were the larger numbers and the high completion rate with 
OCT parameters at 1 year, allowing us to compare the treat-
ment effect with other studies and landmark clinical trial 
outcomes with reasonable confidence.
Conclusion
In this report, we have described our approach to bevaci-
zumab therapy for retinal vein occlusion and also reported 
our outcomes. We have reinforced the justification to use 
bevacizumab, especially if other anti-VEGF agents are 
unavailable. Such evidence from real-world experience 
may be useful as a pragmatic benchmark in future audits 
on outcomes of retinal vein occlusion therapy using either 
bevacizumab or other anti-VEGF agents.
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